NZ's PHARMAC to list Praxbind and achieves price cut on Pradaxa

8 August 2016

New Zealand’s Pharmaceutical Management Agency PHARMAC today announced the approval of an agreement with Boehringer Ingelheim for the listing of Praxbind (idarucizumab) for use in District Health Board (DHB) hospitals, along with price reductions for anticoagulant Pradaxa (dabigatran).

The funding of idarucizumab means that an antidote to dabigatran will be available for use in DHB hospitals from September 1, 2016. Idarucizumab can be used in situations where reversal of the anticoagulant effects of dabigatran is required for emergency surgery/urgent procedures, or situations of life-threatening or uncontrolled bleeding.

Praxbind will be listed under a new Pharmaceutical Schedule subheading, Anticoagulant Reversal Agents in the Antifibrinolytics, Hemostatics and Local Sclerosants therapeutic subgroup of the Blood and Blood Forming Organs therapeutic group), in Part II of Section H of the Pharmaceutical Schedule from September 1, 2016, as follows (ex-manufacturer, excluding GST).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK